ME Stock Recent News

DNA testing firm 23andMe has filed for bankruptcy protection in the US, marking the collapse of one of the most high-profile names in consumer genetics. Co-founder Anne Wojcicki has stepped down as chief executive with immediate effect, though she will remain on the board.

23andMe Holding Co. (NASDAQ: ME) was a hot stock in late 2021, trading at $265.

DNA-testing company 23andMe has filed for bankruptcy in the U.S. and announced the resignation of its chief executive.

Genetic testing firm 23andMe filed for Chapter 11 bankruptcy in the U.S. on Sunday and said it was looking to sell itself.

Intends to use Proceedings to Conduct a Value-Maximizing Sale Process and Resolve Liabilities Company Expects to Continue Business Operations in the Ordinary Course During Proceedings; Secures Commitment for Approximately $35 Million in DIP Financing to Support Ongoing Operations No Changes to Customer Data Management and Access; Company Remains Committed to Transparency Around Customer Data Privacy; Any Buyer will be Required to Comply with Applicable Law with Respect to Treatment of Customer Data Company Announces Board and Leadership Changes to Support Restructuring and Sale Process SAN FRANCISCO, March 23, 2025 (GLOBE NEWSWIRE) -- 23andMe Holding Co. (“23andMe” or the “Company”) (Nasdaq: ME), a leading human genetics and biotechnology company, today announced that it has initiated voluntary Chapter 11 proceedings in the U.S. Bankruptcy Court for the Eastern District of Missouri (the “Court”) to facilitate a sale process to maximize the value of its business. The Company

Provides 23andMe+ Premium members with highly requested insight into their likelihood of developing slightly elevated homocysteine levels Provides 23andMe+ Premium members with highly requested insight into their likelihood of developing slightly elevated homocysteine levels

23andMe's special committee of independent directors on Monday rejected CEO Anne Wojcicki's proposal to take the distressed genetic testing company private. Wojcicki submitted a proposal to the committee on Sunday, offering to acquire all of the company's outstanding shares for 41 cents each.

SUNNYVALE, Calif., March 03, 2025 (GLOBE NEWSWIRE) -- The Special Committee of the Board of Directors of 23andMe Holding Co. (“23andMe” or the “Company”) (Nasdaq: ME) today confirmed receipt of a non-binding proposal from Anne Wojcicki, Chief Executive Officer, Co-Founder, and Chair of the Board of Directors of 23andMe, to acquire all of the outstanding shares of capital stock of 23andMe not owned by Ms. Wojcicki and her affiliates (or any other stockholders that she invites to “roll over” their current equity ownership) for cash consideration of $0.41 per share. Ms. Wojcicki's proposal, which was included in an amended Schedule 13D filing made by Ms. Wojcicki with the Securities and Exchange Commission earlier today, represented an 84% decrease to the $2.53 per share price included in the joint non-binding proposal previously submitted by Ms. Wojcicki and her then co-bidder on February 20, 2025.

Mathew Knowles, Male Breast Cancer Survivor and Father of Beyoncé and Solange, Teams with 23andMe to Discuss the Importance of Genetic Testing in Understanding Cancer Risk Factors Mathew Knowles, Male Breast Cancer Survivor and Father of Beyoncé and Solange, Teams with 23andMe to Discuss the Importance of Genetic Testing in Understanding Cancer Risk Factors

23andMe CEO Anne Wojcicki and New Mountain Capital have submitted a proposal to take the company private. They are offering to buy all outstanding shares in cash for $2.53 per share, or an equity value of approximately $74.7 million.